Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura (9891-08)
Discuss the diagnosis, testing, treatment and outcomes of patients with Thrombotic Thrombocytopenic Purpura (TTP), while adding some details from an historical perspective.
| Code |
9891-08 |
| Level |
Advanced |
Member Price
$0
Non-Member Price
$135
Additional Details
PEP hours: 6
CPS/ART credits: 0.4
Learning Outcomes:
- Describe briefly the history of TTP prior to its link to the von Willebrand factor
- Explain conceptually the clinical difference between a decreased concentration compared to a functionally impaired vWF
- Describe the two primary functions of vWF
- Explain, in general terms, the functional difference between the sizes of circulating vWF multimers
- Outline the effects of DDAVP on the circulating vWF
- List the five features that are considered the hallmark of TTP
- Describe the key clinical reports that outline the key observations linking TTP to the vWF
- Briefly describe the epidemiology of TTP
- List the organ which is thought to be the main production site for ADAMTS-13
- Describe the exact cleavage site for ADAMTS-13 in a vWf multimer
- Outline the genetics of TTP
- Explain the nature of ADAMTS 13 metalloproteinase
- Describe in more detail the clinical findings in TTP
- Discuss the possible mechanisms by which inhibitory antibodies can cause TTP in an affected individual
- Describe the differences between TTP and HUS
- Outline the laboratory approach to confirming the diagnosis of TTP
- Describe the theory of the various approaches of treatment of TTP
- Discuss the relative advantages and disadvantages of the protocols for the treatment of TTP
Instructor: Linda Stang, MLT
Prerequisites: None
Textbook: N/A
Equipment: Computer with Internet is required
Start Date: Upon registration
Completion: Up to 52 weeks
Version Date: October 2008